You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Despite prevalent use of anti-platelet and anti-lipid therapies, stroke remains the third major cause of death and is the leading cause of adult disability in the US with an estimated cost in the range of $34 billion annually. Approximately 20% of the annual 795,000 stroke patients die within one year and 15-30% are permanently disabled. Antiplatelet therapy is mainly used for primary prevention o ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Bounding generalization risk for Deep Neural Networks

    SBC: Euler Scientific            Topic: NGA20A001

    Deep Convolutional Neural Networks (DCNNs) have become ubiquitous in the analysis of large datasets with geometric symmetries. These datasets are common in medicine, science, intelligence, autonomous driving and industry. While analysis based on DCNNs have proven powerful, uncertainty estimation for such analyses has required sophisticated empirical studies. This has negatively impacted the effect ...

    STTR Phase II 2022 Department of DefenseNational Geospatial-Intelligence Agency
  3. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operati ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  4. Development and evaluation of diffuse correlation spectroscopy to monitor cerebral blood flow and detect intraventricular hemorrhage in extremely premature infants

    SBC: 149 MEDICAL INC            Topic: 103

    PROJECT SUMMARY/ABSTRACT Every year in the United States about 30% of the 60,000 infants born extremely premature (andlt;30 weeks gestational age and andlt;1000 g birth-weight [ELGA]) develop intraventricular hemorrhage (IVH). IVH is associated with high risk for cerebral palsy and significant intellectual disability, causing lifelong implications for affected children and their families and consi ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Infant Assessment of Early Communication Risk Factors: The ISCBS (formerly ECBS)

    SBC: PAUL H BROOKES PUBLISHING CO., INC.            Topic: NIDCD

    DESCRIPTION provided by applicant Effective early intervention depends on reliable identification of risk for communication impairments as soon as possible Established infant risk factors for communication impairments include poor turn taking gestures receptive language commenting symbolic play and speech Although these risk factors can be detected by mos and reliably predict late ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A digital tool for monitoring speech decline in ALS

    SBC: MODALITY.AI , INC            Topic: NIDCD

    PROJECT SUMMARY Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease resulting in the progressive loss of limb, trunk, and head and neck (bulbar) motor function and is the most common adult-onset motor neuron disease. The disease is characterized by significant across-patient heterogeneity in the onset region and in pattern and progression rate, making early and accurate diagno ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Antivirals Targeting Flavivirus Envelope Proteins

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide HIV fusion inhibitor, is the prototype for a new class of antivirals that inhibit viral envelope protein structural rearrangements essential for viral entry into host cells. In preliminary experiment ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. MicroFlex Tools to Improve Sinus Diagnostics and Surgery

    SBC: Quest Product Development Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): MicroFlex technology will provide unprecedented flexibility and controllability for the tip of endoscopes, enabling minimally invasive surgery in previously inaccessible spaces, direct visualization of structures there, and fine tool manipulation capabilities for diagnostic, therapeutic and surgical procedures. MicroFlex combines innovations in actuation, sens ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  9. Identification of novel therapeutics for tuberculosis combining cheminformatics,

    SBC: COLLABORATIVE DRUG DISCOVERY, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): We are witnessing the growing menace of both increasing cases of drug-sensitive and drug-resistant Mycobacterium tuberculosis (Mtb) strains and the challenge to produce the first new tuberculosis (TB) drug in well over40 years. The TB community, having invested in extensive high-throughput screening efforts, is faced with the question of how to optimally levera ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Deriving Bone Density from Thoracic CT Scans, STTR Phase II

    SBC: BDI, Inc.            Topic: NIAMS

    ABSTRACT Osteoporosis is a major cause of disability and morbidity in our populationAs many asmillion Americans have osteoporosis andmillion more have osteopeniaHoweverbone mineral densityBMDassessment does not occur in many Americans when indicated and measure currently requires a separate referral and separate imaging scan to obtain BMDThe result is that onlyof Americans who are at risk of suffe ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government